Sr. Director / Executive Director - Biostats
Location: Remote U.S. with periodic travel
About GondolaBio
GondolaBio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. GondolaBio is an independent sister company to BridgeBio, originally carved out in 2024 after securing $300M in private financing from external investors. GondolaBio aims to leverage cutting-edge biological research to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.
Who You Are
You are an experienced biostatistician with deep expertise in rare disease clinical development across the full lifecycle, with Biometrics leadership oversight and a forward-looking regulatory and methods agenda. This role will report into the Chief Development Officer, and be accountable for the statistical and data strategy of the portfolio from FIH through registration and lifecycle management. You thrive in lean, cross-functional settings and bring both methodological rigor and pragmatic judgment to study design and analysis. You are energized by the challenge of extracting meaningful, credible signal from small, heterogeneous patient populations.
Key Responsibilities
Statistical leadership for Oligonucleotide programs:
- Serve as the lead statistician for GondolaBio's ASO and siRNA assets, owning statistical strategy from early FIH through proof-of-concept and pivotal trials. Develop and defend fit-for-purpose statistical analysis plans (SAPs) that account for small sample sizes, placebo and open-label designs, and high inter-patient variability.
- Early signal detection and quantitative decision-making: lead Bayesian go/no-go criteria, probability of success, and assurance calculations for portfolio and stage-gate decisions.
- Pivotal design and registration: lead single-study-plus-confirmatory-evidence strategies, ISS/ISE and integrated summaries, NDA/BLA/MAA statistical sections, responses to information requests, advisory committee preparation and labeling claims
- Portfolio and business development: statistical due diligence on in-licensing and acquisition candidates.
Clinical & Rare disease-adapted trial design:
- Apply specialized methods appropriate for small N studies designs including delayed start, crossover and n-of-1, master protocols, randomized withdrawal and seamless Ph1/2/3
- Design prospective natural history protocols, registry partnerships, and data standards that make the data usable as regulatory-grade external controls.
- Partner with clinical colleagues to define scientifically credible and regulatorily acceptable primary and secondary endpoints.
- Lead disease progression model development from natural history and registration trial data to choose endpoints, enrich populations and project long-term benefit; partner with Pharmacometrics in connecting to MIDD work with Clinical Pharmacology.
- Integrate external controls and real-world data using target trial emulation, propensity-score and covariate-balancing methods, quantitative bias and sensitivity analyses, Bayesian primary inference and dynamic borrowing. ML-based prognostic covariates for covariate adjustment.
- Proactively identify and mitigate risks from high variability, missing data, and limited statistical power, communicating trade-offs clearly to program leadership.
Global regulatory statistical leadership:
- Prepare and contribute to statistical sections of INDs, , FDA/EMA meeting briefing and scientific advice documents, qualification opinions for novel endpoints or natural history tools, pediatric extrapolation, PIP/iPSP strategies. Support pre-IND , EoP2, pre-NDA/BLA meetings, and respond to agency questions on statistical methodology.
- Build and lead biostat, statistical programming and data management organization, including hybrid in-house plus FSP/FSO sourcing model, vendor selection and oversight to support clinical, translational and nonclinical data analytics and deliverables. AI/ML and data science including automation in programming is a plus.
Cross-functional collaboration:
- Partner closely with Clinical Development, Clinical Pharmacology, Pharmacometrics, Regulatory, Clinical Operations, and external CROs/vendors to ensure statistical considerations are embedded early in protocol development, CRF design, data management, and study conduct. Represent Statistics in cross-functional program team meetings.
- Collaborate with Nonclinical and translational teams, and Clinical teams to develop analysis plans for PD biomarkers, target engagement endpoints, and patient stratification.